60. Move to a new pricing model for the Point of Care (POC) m-PIMA molecular diagnostic system for EID and VL assays that is an all inclusive price (including instrument, data services, connectivity, service and maintenance) of $30 per test, moving down to $15 per test with sufficient aggregate EID and VL volumes.
61. To complement existing HIV, viral hepatitis, TB, haemorrhagic fever and other important infectious disease assays, Abbott will to continue to develop additional assays of strategic importance across the platforms.
62. Commit to coordinate across business divisions to provide the most comprehensive solution of centralized and decentralized molecular platforms for each country.
63. Continue to implement consistent and transparent pricing, communicating openly on volume requirements for pricing levels.
Commitments 60 & 61:
VL for mPima received WHO prequalification.
Now offering a 20/cartridge all in cost, in some countries including delivery or cartridge to site level.
22. Make every effort to stay in the EID market to ensure there is a sufficient testing capacity to reach and maintain accelerated Fast Track targets (95% of HEI tested by 2020 and beyond).
23. Ensure consistent reagent pricing across partners within countries and within regions, and provide a transparent breakdown of pricing for the products and services sold.
24. Consider moving from separate instrument, consumable, and service procurement towards more consolidated, ideally all-inclusive pricing models.
25. Provide service level agreements that clearly spell out key performance indicators POC, near POC, and high-throughput laboratory instruments, including target up-times and failure rate threshold (with consideration for different causes), plus a mitigation plan when the threshold is exceeded.
26. Consider the inclusion of a clinical indeterminate range in test result reports for more accurate diagnosis of infants per WHO guidelines.
27. Rapidly communicate stock shortages with major buyers and work on joint mitigation strategies.